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checkpoint that limits immune responses by delivering potent
inhibitory signals to T cells on interaction with specific ligands
expressed on tumor/virus-infected cells, thus contributing to
immune escape mechanisms. Therapeutic PD-1 blockade has
been shown to mediate tumor eradication with impressive
clinical results. Little is known about the expression/function of
PD-1 on human natural killer (NK) cells.
Objective: We sought to clarify whether human NK cells can
express PD-1 and analyze their phenotypic/functional features.
Methods: Weperformedmultiparametric cytofluorimetric analysis
of PD-11 NK cells and their functional characterization using
degranulation, cytokine production, and proliferation assays.
Results: We provide unequivocal evidence that PD-1 is highly
expressed (PD-1bright) on an NK cell subset detectable in the
peripheral blood of approximately one fourth of healthy
subjects. These donors are always serologically positive for
human cytomegalovirus. PD-1 is expressed by CD56dim but not
CD56bright NK cells and is confined to fully mature NK cells
characterized by the NKG2A2KIR1CD571 phenotype.
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http://dx.doi.org/10.1016/j.jaci.2016.04.025possible induction/expansion in tumor environments. Functional
analysis revealed a reduced proliferative capability in response
to cytokines, low degranulation, and impaired cytokine
production on interaction with tumor targets.
Conclusions: We have identified and characterized a novel
subpopulation of human NK cells expressing high levels of PD-1.
These cells have the phenotypic characteristics of fully mature
NK cells and are increased in patients with ovarian carcinoma.
They display low proliferative responses and impaired
antitumor activity that can be partially restored by antibody-
mediated disruption of PD-1/programmed death ligand
interaction. (J Allergy Clin Immunol 2017;139:335-46.)
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The programmed death 1 (PD-1; CD279) gene belongs to the
immunoglobulin gene super family and encodes a 55-kDa type I
transmembrane protein.1,2 The protein’s structure includes an
extracellular IgV domain, followed by a transmembrane region
and a cytoplasmic tail. The intracellular tail contains 2 phosphor-
ylation sites, one located in an immunoreceptor tyrosine–based
inhibitory motif and the other in an immunoreceptor tyrosine–
based switch motif.
PD-1 is involved in peripheral tolerance because of its ability to
inhibit cytolytic effector T cells and to prevent their attack on
certain normal tissues. In particular, PD-1 functions as an immune
checkpoint that, in concert with other checkpoints, prevents
overreaction of the immune system and consequent tissue
damage.3
However, in contrast to this important beneficial role in
maintaining peripheral tolerance and T-cell homeostasis, on
interaction with PD-1 ligands (PD-L1 [CD274] and PD-L2
[CD273]) expressed on tumor-infected and/or virus-infected
cells, PD-1 inhibits T-cell function, contributing to immune
escape mechanisms frequently occurring in patients with cancer
and chronic viral infections.4 In particular, in activated T cells the
engagement of PD-1 by its ligands expressed on cancer cells pre-
vents the expansion and function of effector T cells (leading to the
generation of ‘‘exhausted’’ T cells), thus resulting in severe
impairment of antitumor and antiviral T-cell responses.5-8
Remarkably, IFN-g is a potent inducer of PD-L1 expression,9
suggesting that the immune responses mediated by TH1/natural
killer (NK) cells or the IFN-g therapy itself might favor PD-1–
mediated tumor evasion.
PD-1 has unique functional characteristics related to those of
cytotoxic T-lymphocyte antigen 4 (CTLA-4; CD152), a major335
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both cell-intrinsic (ie, on CTLA-41 effector cells) and extrinsic
(on forkhead box P3–positive regulatory T cells) activities. As a
consequence, deficiency in CTLA-4 function results in severe
antigen-nonspecific autoimmune phenotypes.10 In contrast, the
effect of engaging PD-1 is mainly cell intrinsic. The cell-
intrinsic function of PD-1, as well as the regulation of PD-1
expression, might be responsible for the chronic and relatively
milder pathologic phenotypes resulting from PD-1 blockade
through either antibody-masking or genetic manipulation.
Antibody-mediated blocking of PD-1 is now being exploited in
clinics as a therapeutic tool for boosting immune responses in pa-
tients with different diseases, primarily in cancer. Importantly,
targeting PD-1/PD-L1 interactions can also improve the efficacy
of adoptive cell therapies in tumors or chronic viral infec-
tions.11-14 In some instances PD-1 blockade has been shown to
mediate tumor eradication,15-17 resulting in impressive and highly
encouraging clinical results. Indeed, accumulating data indicate
that the administration of an mAb to PD-1, used alone or in com-
bination with other drugs, might provide a highly successful ther-
apeutic tool in different types of advanced tumors, including
melanoma, lung cancer, and ovarian carcinoma.18-20
NK cell function is regulated by an array of germline-encoded
surface receptors that, on interaction with their ligands, transmit
either inhibitory or activating signals.21-23 Mature human NK
cells express inhibitory receptors specific for HLA class I mole-
cules, including killer immunoglobulin-like receptors (KIRs),
which are able to discriminate among different HLA-A, HLA-
B, and HLA-C allotypes,24 and the CD94/NKG2A heterodimer
specific for HLA-E.25,26 These receptors allow NK cells to spare
HLA class I1 autologous normal cells and to kill cells in which
HLA class I expression is downregulated (eg, by tumor transfor-
mation or viral infection) or allogeneic cells expressing nonself
HLA class I alleles unable to engage inhibitory KIRs (an event
that can occur in the haploidentical hematopoietic stem cell
transplantation setting).27,28 Among the non–HLA-specific
triggering receptors, NKp46, NKp30, NKp44 (collectively
termed natural cytotoxicity receptors [NCRs]),22 NKG2D,29
DNAX accessory molecule-1 (DNAM-1; CD226),26 and CD16
play a major role in NK cell activation. In addition, human NKcells can express HLA class I–specific activating receptors,
including KIR2DS1,30,31 KIR2DS4,32,33 and CD94/NKG2C.26
Twomain NK cell subsets characterized by distinct phenotypic
and functional properties have been described, namely the
CD56brightCD162/low and CD56dimCD161 subsets. CD56bright
NK cells express high levels of CD94/NKG2A but virtually no
KIRs. Infrequent in peripheral blood (PB; approximately 10%),
they predominate in secondary lymphoid compartments.
CD56bright NK cells produce high amounts of immunoregulatory
cytokines but are poorly cytotoxic. In contrast, the CD56dim
subset is largely represented in PB (approximately 90%) and is
characterized by high surface expression of KIRs, high cytotoxic
activity against tumor- and virus-infected targets, and rapid
production of cytokines on receptor-mediated cell activation.34,35
A constitutive or inducible expression of PD-1 has been
detected in different cell populations, including T, B, and myeloid
cells,14,36 whereas little is known regarding PD-1 expression on
NK cells to date. In human subjects it has been reported that
NK cells from patients with multiple myeloma37 or patients
with posttransplantation lymphoproliferative disorders38 can
express low PD-1 levels. On the other hand, expression of PD-1
by resting NK cells from immunocompetent healthy subjects
has been poorly defined.
In the present study we show that PD-1 is expressed at high
levels (PD-1bright) on a discrete subset of mature
CD56dimNKG2A2KIR1CD571 NK cells in approximately one
fourth of a large number of donors with no evident disease (there-
after defined as healthy donors [HDs]) and, more frequently, in the
PB of a cohort of patients with ovarian carcinoma. Functional
analysis revealed that PD-11 NK cells display poor cytokine-
induced proliferation and lower degranulation and cytokine
production compared with PD-12 cells. Antibody-mediated
disruption of the PD-1/PD-L interaction could revert, at least in
part, the impaired NK cell degranulation against an ovarian
carcinoma cell line. Remarkably, a relatively large PD-1bright
NK cell subset was detected in peritoneal fluid/ascites (PF) of
patients with ovarian carcinoma, suggesting that PD-11 cells
can be induced by the tumor microenvironment or recruited
to the tumor site. Also, in this case the impaired NK cell
degranulation was reversible with anti–PD-L antibodies.
METHODS
Patients and samples
This study included 200 buffy coats collected from volunteer blood donors
admitted to the blood transfusion center of IRCCS S. Martino-IST after
obtaining informed consent, and the study was approved by the Ethical
Committee of IRCCS S. Martino-IST (39/2012). Thirty patients with
seropapillary ovarian carcinoma subjected to primary surgery before chemo-
therapy (in accordance with a protocol approved by the Spedali Civili of
Brescia institutional ethical board) were also enrolled, and informed consent
was obtained from all patients according to the Declaration of Helsinki.Isolation, culture of human leukocytes, and gate
strategy
Mononuclear cells were obtained from heparinized PB39 and from PF of
patients with ovarian carcinoma (after depletion of epithelial cell adhesion
molecule [ESA]1 and CD901 cells by using Magnetic Dynabeads Goat
anti-Mouse IgG)40 by means of density gradient centrifugation over Ficoll
(Sigma, St Louis, Mo) and then resuspended in RPMI 1640 supplemented
with 2 mmol/L glutamine, 50 mg/mL penicillin, 50 mg/mL streptomycin,
and 10% heat-inactivated FCS (Societa Prodotti Antibiotici, Milano, Italy).
FIG 1. PD-11NK cells in the PB of HDs.A, The x-axis represents the percentage of PD-11NK cells of 200 HDs.
The y-axis represents the various donors with NK cells at different PD-11 percentages. B, Cytofluorimetric
analysis of PD-1 expression in PB NK cells of 4 representative donors. C, Cytofluorimetric analysis of PD-1
expression in PB NK cells of 2 representative PD-11 donors at different time points. Gate strategy used: A.
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For more information on gate strategies, see Fig E1 in this article’s Online
Repository at www.jacionline.org. In Fig 1 analysis of NK cells was made on
CD561/2CD32CD202CD161/2 gated cells (gate strategy A). In Fig 2 anal-
ysis of NK cells was made on CD561CD32CD202CD161/2 gated cells
(gate strategy B). In Figs 3 and 4 (panels A and C) and Figs 5, 6, and 7 (panel
A) analysis of PD-11 and PD-12 NK cell subsets was made on
CD56dimCD32CD202CD161/2 gated cells (gate strategy C). In Figs 4 (panel
B) and 7 (panels B and C) analysis of PD-11 and PD-12 NK cell subsets wasmade on CD56dimCD32CD202CD161/2NKG2A2KIR1CD571 gated cells
(gate strategy D). In Fig 8 analysis of NK cells was made on
CD561/2CD32CD202CD161/2 gated cells (gate strategy A), as in Fig 1.Statistical analysis
The independent samples t test was used for evaluating quantitative vari-
ables. The test is a statistical technique used to analyze the mean comparison
of 2 independent groups. The statistical level of significance was preset at .05.
FIG 2. Expression of NKG2C and Siglec-7 in PB NK cells of representative PD-11 and PD-12 HDs. A, Percent-
ages and geometric means in 50 donors. ***P < .001. B, Cytofluorimetric analysis of PD-1, NKG2C, and
Siglec-7 expression in NK cells of 1 PD-11 and 1 PD-12 donors. B7-H3 was used as a negative control. C, Per-
centage of seropositivity for HCMV in sera derived from 40 donors expressing or not expressing PD-1 on NK
cells. Gate strategy used: B.
FIG 3. Expression of informative surface receptors in PD-11 and PD-12NK cell subsets from PB of represen-
tative PD-11HDs.A, Percentages and geometricmeans in 15 donors. **P < .01 and ***P < .001. B,One repre-
sentative donor. Gate strategy used: C.
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Statistics, version 18.0, software (formerly SPSS Statistics; IBM, Segrate,
Italy) and GraphPad Prism 6 (GraphPad Software, La Jolla, Calif).RESULTS
PD-1 can be expressed by NK cells of HDs
Freshly isolated PB lymphocytes from a cohort of 200 HDs
were assessed for the expression of PD-1 on NK cells by using
cytofluorimetric analysis.
A subset characterized by a bright surface PD-1 expression was
detected in about 25% of the donors analyzed (Fig 1, A and B).
PD-11 cells were confined to CD56dim NK cells, whereas the
CD56bright subset was consistently PD-12 (Fig 1, B). The percent-
age of PD-11 cells was variable among donors, ranging between
1.5% and 10%. In one donor displaying an expansion of the
aberrant CD562CD161 NK subset,41,42 PD-1 was found on
both CD56dim and CD562 NK cells, and the percentage of
positive cells reached as much as 49% (Fig 1, B).Notably, analysis of the size of the PD-11 subset at different
time points in various subjects revealed substantial stability
over time. In Fig 1, C, 2 representative HDs are shown in whom
the expression of PD-1 was unchanged for at least 1 year.
Because PD-11 NK cells were present only in some donors, it
is possible that the expression of PD-1 might be related to infec-
tion. In this regard recent studies indicated that human cytomeg-
alovirus (HCMV) infection leads to NK cell differentiation/
maturation and a reconfiguration in the NK cell receptor reper-
toire, including upregulation of the NKG2C activating receptor43
and downregulation of the sialic acid–binding immunoglobulin-
like lectin (Siglec) 7 (or p75/AIRM-1) inhibitory receptor.42,44-46
Thus we analyzed PD-11 and PD-12 donors to figure out whether
the expression of PD-1 correlated with altered expression of these
NK cell markers.
We found that PD-11 subjects frequently display high propor-
tions of NKG2C1 cells, as well as a subset of Siglec-72 NK
cells (Fig 2, A and B). In addition, in most PD-11 donors the
NKG2C1 cell expansion was characterized by expression of an
FIG 4. Analysis of additional markers on PD-11 and PD-12 PB NK cells in representative PD-11 HDs. A, Per-
centages of expression of the indicatedmarkers in 8 PD-11 donors. Gate strategy used: C. *P < .05, **P < .01,
and ***P < .001. B, Expression of NCRs on PD-11 and PD-12 cells in CD56dimNKG2A2KIR1CD571 gated cells
in 1 representative donor. Gate strategy used: D. C, PD-11 NK cells (black circles) in relation to NCRs and
CD57 surface expression (1 representative donor). Gate strategy used: C.
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results suggested a possible association between PD-1
expression in NK cells and HCMV infection.42,45,46,49 Thus,
when possible, HCMV seropositivity was also analyzed. We
found that all the PD-11 subjects were seropositive for HCMV
(Fig 2, C).
Previous studies revealed that, among the surface molecules
undergoing changes in expression after HCMV infection, an
important group is represented by the HLA-specific receptors,
including NKG2A, KIR, and leukocyte immunoglobulin-like
receptor 1 (LIR-1). In particular, infection by HCMV favors
expansion of KIR1 and LIR-11NK cells while reducing the frac-
tion of NKG2A1 NK cells.42,46 In addition, a subset of
NKG2A2KIR1LIR-11 NK cells preferentially acquired
CD57.49 This molecule constitutes a marker of unknown function
that is thought to identify mature/terminally differentiated NK
cells. CD571 NK cells appear to be a stable subpopulation,
increasing with age and exposure to pathogens (especially
HCMV).
By comparing the PD-11 and PD-12 NK cell subsets derived
from seropositive PD-11 HDs, we show that the PD-11 popula-
tion is primarily composed of mature NKG2A2KIR1LIR-11
cells expressing CD57 (Fig 3, A). In addition, different fromPD-12 NK cells, only a minor fraction of PD-11 NK cells
expressed Siglec-7 (Fig 3, A and B), whereas NKG2C was
expressed on both PD-11 and PD-12 NK cells (Fig 3, A and B).
Fig 3, B, shows expression of the above markers on PD-11 and
PD-12 cells of a representative donor.
Further analysis of additional cell-surface markers undergoing
variation after HCMV infection in the PD-11 NK cell subset
showed lower levels of NKp46, NKp30, CD160, and CD62 ligand
expression (Fig 4, A) compared with the PD-12 subset. On the
other hand, perforin/granzyme and CD16 were expressed at
higher levels in PD-11 NK cells. Other receptors/markers,
including 2B4 (CD244), IL-18 receptor a (IL-18Ra), NKG2D,
and DNAM-1, were expressed at similar levels in PD-11 and
PD-12 cells (Fig 4, A, and data not shown). The activation
markers CD69, CD25, and NKp44 were substantially negative
on both NK cell subsets (data not shown).
Finally, comparison between the PD-11 and PD-12 cell
fractions of the (highly differentiated) NKG2A2KIR1CD571
subset revealed that PD-11 cells display the lowest expression
of NKp46 and NKp30 (Fig 4, B and C). Altogether, these
data indicate that expression of PD-1 is confined to NK cells
with the phenotypic features of fully mature (terminally
differentiated) NK cells.50-52
FIG 5. Degranulation (CD107a expression) of PD-11 and PD-12 NK cells from representative PD-11 HDs
stimulated with the indicated tumor target cells.A and E, K562 (6 donors and 1 representative donor, respec-
tively). B, P815 alone (CTR) or with the indicated mAbs (6 donors). C and F, P815 with the indicated mAbs
with or without anti–PD-1 mAb (6 donors and 1 representative donor, respectively). D and G,OVCAR5 alone
or in the presence of the indicated mAbs (6 donors and 1 representative donor, respectively). *P < .05 and
**P < .01. Gate strategy used: C.
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These experiments were performed on gated PD-11 or PD-12
CD56dim NK cell subsets by evaluating NK cell degranulation,
as assessed based on surface expression of CD107a on interac-
tion with different target cells. First, PD-11 and PD-12 fractions
were comparatively analyzed for their ability to undergo
degranulation in the presence of K562 erythroleukemia. K562
is a classical NK cell target lacking HLA class I molecules
and expressing a series of ligands for activating NK receptors,
including B7-H6,53 which is recognized by NKp30. As shown
in Fig 5, A and E, degranulation in PD-11 NK cells (NKp30low
and NKp46low) was markedly less than in PD-12 NK cells
(NKp30high and NKp46high). Because K562 cells do not express
PD-L1/PD-L2, the differences detected could not reflect the
interaction between PD-1 and its ligands but rather the low
expression of the 2 main NCRs. Next, PD-11 and PD-12 NK
cell subsets were assessed for degranulation in a reverse
antibody-dependent cellular cytotoxicity (R-ADCC) assay
against the murine FcgR1 P815 mastocytoma cell line (PD-
L1/PD-L2 negative). These experiments were performed in
the absence or presence of mAbs specific for triggering NK re-
ceptors. The aim was to assess possible additional differences in
degranulation after mAb-mediated cross-linking of activating
receptors and coreceptors. As shown in Fig 5, B, both NK sub-
sets undergo efficient degranulation in the presence of anti-
CD16 or anti-NKp46 mAbs. However, in PD-11 cells the low
surface expression of NKp46 resulted in less efficient responses
to anti-NKp46 mAb. Interestingly, the 2 subsets displayeddifferent abilities to respond to other triggering stimuli. Thus
the combined use of mAbs specific for DNAM-1 and 2B4 cor-
eceptors induced degranulation of PD-12 but not PD-11 NK
cells (Fig 5, B).
Another series of R-ADCC experiments was performed by
using anti–PD-1 mAb in combination with anti-NKp46 or anti-
CD16 mAbs. The aim of these experiments was to assess whether
mAb-mediated cross-linking of PD-1 could inhibit NK cell
activation induced by cross-linking of the triggering receptors.
As shown in Fig 5, C and F, mAb-mediated cross-linking of PD-1
resulted in a partial but significant reduction of NK cell responses
to triggering receptors.
We further analyzed the effect of engagement of PD-1 by its
ligands (PD-L1/PD-L2) expressed on the tumor cell line
OVCAR5 (ovarian carcinoma).54 In these experiments the
expression of CD107a on NK cells was analyzed after short-
term exposure of NK cells to OVCAR5 in the presence or absence
of anti–PD-L1/PD-L2 mAbs, which are capable of blocking the
interaction between PD-1 and its ligands (mAb-mediated mask-
ing experiments). As shown in Fig 5, D and G, PD-12 NK cells
displayed a substantial mobilization of CD107a, both in the
absence and presence of anti–PD-L1/PD-L2 mAbs. In contrast,
degranulation of PD-11 NK cells was reduced and could be
restored, at least in part, by anti–PD-L1/PD-L2 mAbs. Note that
we performed experiments also in the presence of anti–HLA class
I mAbs (A6/136)55 to disrupt the inhibitory interaction between
KIRs and HLA class I molecules (expressed at high levels on
the surface of OVCAR5; Fig 5, D and G).
FIG 6. IFN-g and TNF-a production by PD-11 and PD-12 PB NK cells from representative PD-11 HDs after
stimulation with different tumor target cells.A and C, IFN-g production after stimulation with K562 (6 donors
and 1 representative donor, respectively). E and G, TNF-a production after stimulation with K562 (6 donors
and 1 representative donor, respectively). B and D, IFN-g production on stimulation with P815 in the pres-
ence or absence of the indicated mAbs (6 donors and 1 representative donor, respectively). F and H, TNF-a
production on stimulation with P815 in the presence or absence of the indicated mAbs (6 donors and 1
representative donor, respectively). *P < .05 and **P < .01. Gate strategy used: C.
FIG 7. Proliferative responses to cytokines of PD-11 and PD-12NK cells in representative PD-11 HDs. A, Pro-
liferation (CFSE staining) of PD-11 and PD-12 CD56dim NK cells. Gate strategy used: C. B, Proliferation (CFSE
staining) of PD-11 and PD-12 CD56dimNKG2A2KIR1CD571 NK cells. Gate strategy used: D. C, Proliferation
(CFSE staining) of PD-11 and PD-12 CD56dimNKG2A2KIR1CD571 NK cells. 0-4, Number of cell generations
in CFSE-stained proliferating cells. Gate strategy used: D. *P < .05.
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 1
PESCE ET AL 341Altogether, these experiments indicate that PD-11 NK cells
display a low cytolytic activity against tumor targets, even
when these cells lack PD-L1/PD-L2 expression (ie, K562). Inaddition, the inhibition of NK cell degranulation induced by
cross-linking PD-1 and its ligands on OVCAR5 tumor cells was
reverted only in part by mAbs specific for PD-L1/PD-L2.
FIG 8. PD-11 NK cells in PF and PB in representative patients with ovarian carcinoma. A, The x-axis repre-
sents the percentage of PD-11 NK cells derived from PB or PF of 30 patients. The y-axis represents the
various donors with NK cells at different PD-11 percentages. Gate strategy used: A. B, PD-1 percentages
in 2 representative patients. Gate strategy used: A. C, Comparison of the percentages of PD-11 NK cells be-
tween HDs (PB) and patients (PB and PF). Gate strategy used: A.D and E,Degranulation (CD107a expression)
of PD-11 and PD-12NK cells from representative PD-11 patients stimulated with OVCAR5 tumor target cells
in the presence of the indicated mAbs (3 patients and 1 representative patient, respectively). Gate strategy
used: C. *P < .05 and ***P < .001.
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(compared with PD-12) cells could be overcome by strong stim-
uli, such as cell triggering through CD16 (in R-ADCC). In this
case it is likely that the low level of NCR expression by PD-11NK cells might be counterbalanced (at least in part) by the expres-
sion of high levels of CD16 and perforin/granzyme (Fig 4, A).
Cells were stimulated with K562 or P815 tumor target cells and
assessed for production of IFN-g and TNF-a in a flow cytometric
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NK cells would also display an altered capability of releasing
cytokines. As shown in Fig 6, K562-induced NK cell activation
resulted in production of IFN-g (Fig 6, A and C) and TNF-a
(Fig 6, E and G) by most PD-12 but only a small fraction of
PD-11 NK cells. Remarkably, similar to degranulation, IFN-g
and TNF-a production could be induced in PD-11 NK cells by
anti-CD16 mAbs in a redirected-antibody dependent stimulation
assay (P815 cells plus mAb). On the other hand, when anti-CD16
was combined with anti–PD-1mAb, a significantly lower fraction
of PD-11NK cells produced cytokines compared with PD-12NK
cells (Fig 6, B, D, F, and H).
Next, the PD-11 and PD-12 subsets were analyzed for their ca-
pacity to proliferate (by using the carboxyfluorescein succinimidyl
ester [CFSE] dilution assay measured at 5 days of culture) in
response to rhIL-2 or rhIL-15. As shown in Fig 7, A, PD-11 NK
cells are poorly responsive to low doses of rhIL-2 or rhIL-15,
whereas they undergo proliferation at higher cytokine doses,
although at lower rates than PD-12 NK cells. A similar difference
in the capacity to respond to cytokines was observed also between
the PD-11 and PD-12 cell fractions of the NKG2A2KIR1CD571
NK cell population (Fig 7, B). Thus proliferation of PD-11 NK
cells is impaired in the presence of low cytokine concentrations,
a condition that can occur in certain tumor microenvironments.
Fig 7, C, shows comparison of the peaks of CFSE dilution in
PD-11 and PD-12 cells in the presence of rhIL-2. In this case
the culture time was extended to 14 days instead of 5 (standard
time frame) to better visualize the proliferation peaks.Expression and function of PD-1 on NK cells from
patients with tumors
In these experiments we analyzed whether PD-11 NK cells
could be found also in PB and PF of patients affected by
seropapillary ovarian carcinoma.40 PD-11 cells could be detected
in the PB of the majority of these patients. In addition, in given
patients they were present in higher proportions in PF than in
PB of the same patients (Fig 8, A and C). Although, as previously
reported,40 the size of the CD56bright NK cell subsets was usually
larger in PF NK cells compared with PB NK cells of the same
patients, PD-11 NK cells were confined to the CD56dim NK
cell subset (Fig 8, B). Notably, the size of the PD-11 NK cell
subsets detected in PB of the patients was slightly larger than in
PBs of HDs (Fig 8, C).
Altogether, these data indicate that PD-11 NK cells might be
significantly enriched at the tumor site. As shown in Fig 8, D
and E (and not shown), and in agreement with data obtained in
HDs, the ability of PD-11 PF NK cells to degranulate was lower
than that of PD-12 PF NK cells. Note that the use of mAbs
suitable for disrupting the interaction between PD-1 and its
ligands might restore the altered functional capability of PD-11
NK cells toward PD-L1/PD-L21 tumor target cells (OVCAR5,
ovarian carcinoma) (Fig 8, D and E). This suggest that in patients
with ovarian carcinoma, the impaired functional capability of
PD-11 NK cells can be rescued in vivo by mAbs targeting the
PD-1/PD-L axis of the NK/tumor crosstalk.DISCUSSION
In the present study we show that PD-1 is brightly expressed by
a subset of PBNK cells in a fraction of otherwise healthy subjects.PD-1 expression is restricted to the CD56dim NK cell subset and
varies in size among different subjects. The surface phenotype
of PD-11 NK cells is typical of terminally differentiated
(NKG2A2KIR1CD571) NK cells, which are characterized by
low NCR and high CD16, perforin, and granzyme expression.
As to their functional capabilities, PD-11NK cells show impaired
proliferative responses to exogenous rhIL-2 and rhIL-15. In addi-
tion, degranulation/cytotoxic activity and cytokine production in
response to tumor cells are significantly lower in PD-11 than PD-
12 NK cells.
The expression and function of PD-1 have been analyzed
mainly in normal peripheral T cells and tumor-infiltrating
lymphocytes,56-58 whereas only a few studies have been focused
on NK cells. In these studies the expression of PD-1 was detected
in PB NK cells derived from patients37,38,59,60 but not from HDs.
In addition, the level of expression reported was very low, thus
rendering it difficult to discriminate between PD-11 and PD-12
cells and to identify a distinct subset of PD-11 cells. Because
of these limitations, no attempts have been made to characterize
the PD-11 NK cell subset for phenotypic and functional
properties.
Here we show that some HDs express sizeable levels of PD-1
on CD56dim NK cells and that the size of the PD-11 NK cell sub-
set varied among donors. Notably, analysis of the size of the
PD-11 subset in given subjects at different time points revealed
a substantial stability (Fig 1, C). The fact that a PD-11 NK cell
subset could be detected in only some of the subjects analyzed
might be a result of latent chronic infections affecting these sub-
jects (in this context it is of note that an increase in PD-11
lymphocyte numbers has been associated with hepatitis C virus,
hepatitis B virus, and HIV infections).6,7,61-63 Although a correla-
tion exists between the presence of PD-11 NK cells and HCMV
infection, phenotypic analysis of PD-11 NK cells showed that
NKG2C (the expression of which is associated to HCMV infec-
tion) is not preferentially expressed by PD-11 cells. However,
similar to NKG2C1 NK cells accumulating in response to
HCMV infection, the PD-11 subset was almost exclusively
composed of highly differentiated NKG2A2KIR1CD571 NK
cells. In line with this phenotypic feature, PD-11 cells expressed
very low levels of NCRs (the lowest among CD571NK cells) but
high levels of CD16. Conceivably, the impaired degranulation and
cytokine production in response to tumor target cells (K562) is
consequent to the defective expression of NCRs. In this context
it is of note that B7-H6, a major surface ligand of NKp30, is ex-
pressed by K562 cells.53 On the other hand, in line with their high
content of perforin/granzyme and their high expression of CD16,
PD-11NK cells could degranulate to levels comparable with PD-
12 cells in response to anti-CD16 mAbs in R-ADCC.50-52 Thus
under this experimental condition, the impaired degranulation
of PD-11 NK cells caused by downregulation of NCRs (NKp30
and NKp46) can be bypassed by a potent stimulus delivered by
CD16. Based on the recovery of different functions (cytokine
release and cytotoxicity) on cell triggering through CD16 in R-
ADCC, it is unlikely that PD-11NK cells merely represent a pop-
ulation of exhausted cells with an intrinsic functional defect.
Indeed, their functional impairment appears to be mainly conse-
quent to a profound imbalance between inhibitory and triggering
signals, reflecting the upregulation/downregulation of different
receptors. Notably, in line with this concept, the reduced degran-
ulation of PD-11 cells after interaction with OVCAR5 reflects not
only the poorNCR-mediated cell activation but also the inhibitory
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expressed on these target cells. In this case disruption of the
PD-1/PD-L interaction mediated by anti–PD-L mAbs could
partially revert functional inhibition. Thus cross-linking of
PD-1 mediated by either anti–PD-1 mAbs in R-ADCC
(Fig 5,C andF) or by the engagement of PD-L expressed on target
cells (Fig 5, D and G) can lead to impaired PD-11 NK cell
function.
The sharply reduced proliferative responses of PD-11NK cells
to low concentrations of exogenous rhIL-2 and rhIL-15 is in line
with the finding in mice that highly differentiated memory NK
cells display reduced responses to soluble microenvironmental
cytokines.64 Thus it is conceivable that also human CD571 NK
cells can be poorly responsive because they express low amounts
of CD122 (IL-2 receptor b, a subunit of the shared receptor for
IL-2 and IL-15).50-52,65 In addition, the PD-11 NK cell subset is
characterized by the lowest CD122 expression among CD571
NK cells (data not shown). Moreover, IFN-g production by
PD-11 NK cells in response to exogenous rhIL-12 plus rhIL-18
was highly defective (data not shown).50-52 Thus it is conceivable
that PD-11 NK cells might represent a population of poorly
proliferating cells that could be induced to divide only by high
concentrations of microenvironmental cytokines, as suggested
by our present data.
PD-11 NK cells were detected more frequently in the PB of a
cohort of patients with seropapillary ovarian carcinoma than in
HDs. More importantly, PD-11 cells could be recovered from
the PF of most of these patients.40 Remarkably, the size of such
PF PD-11 subsets was much larger than in PB from the same
subjects. In some patients PD-11 NK cells were present in PF
but not in PB. It is possible that in these cases the size of the
PB PD-11 subset could be less than the limit of detectability.
Altogether, these data suggest that PD-11 NK cells are present
more frequently in the PB of patients with certain tumors. In
addition, this PD-11 subset might be greatly increased in size
in tumor-associated NK cells, as in the case of PF. Functionally,
PD-11 NK cells isolated from PF display frequently a markedly
compromised capability of degranulating on interaction with
PD-L1/PD-L21 tumor target cells. Remarkably, mAb-mediated
disruption of PD-1/PD-L interaction could partially restore the
NK cell function.
Because PD-11 cells have been detected in some HDs, it is
possible that latent chronic diseases (eg, viral infections) might
be responsible for PD-1 induction in NK cells. Indeed, a
correlation has been established between HCMV seropositivity
and the presence of PB PD-11 NK cells (Fig 2, C). One might
speculate that both virus-driven signals and the tumor
microenvironment can contribute to PD-1 expression on NK cells
in the case of patients with ovarian carcinoma.
It is evident that the study of other tumors and infectious
diseases is needed to further confirm a correlation with the
presence/induction of PD-11 cells. Remarkably, in a recent study,
the clinical efficacy of an anti–PD-1 mAb has been reported in
patients with ovarian carcinoma.66 It is possible that the beneficial
effects documented in this study might reflect not only a blockade
of PD-1/PD-L on tumor-infiltrating lymphocytes but also on
PD-11 NK cells.
In conclusion, because NK cells are potent effectors with
strong cytolytic activity against tumor cells, the finding that PD-1
can be expressed on these cells, particularly in patients with
cancer, suggests a possible involvement of the PD-1–mediatedinhibitory pathway in the impaired NK cell responses against
tumors. Our present finding further supports the notion that PD-1
signaling might downregulate not only cytotoxic T lymphocyte–
mediated adaptive responses but also innate responses. Therefore
it is conceivable that therapies targeting the PD-1/PD-L axis
might rescue not only cytotoxic T-lymphocyte activity but also
NK-mediated function. In this context it should be stressed that
although in conventional NK cells the effector function is
primarily regulated by HLA class I–specific inhibitory receptors
(KIR family and CD94/NKG2A)/HLA class I molecule
interactions, in the case of PD-11 NK cells, an additional potent
inhibitory pathway might contribute to limit NK cell function. In
this case downregulation of HLA class I molecules on tumor cells
can be offset by the expression of PD-1 ligands. It is possible that
the simultaneous expression of PD-1 together with given
inhibitory HLA-specific receptors might provide an additional
level of suppression of NK cell antitumor responses and that
(mAb-mediated) blocking of different inhibitory checkpoints,
including PD-1, might be required to obtain optimal NK cell
responses.
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Key messages
d Unequivocal evidence that PD-1 is highly expressed by a
subset of NK cells detectable in a fraction of healthy
subjects.
d PD-11 NK cells are CD56dimNKG2A2KIR1CD571, a
phenotypic feature typical of terminally differentiated
NK cells. On interactions with tumor cells, they display
impaired degranulation/cytotoxic activity and cytokine
production and elicit poor proliferation in response to
exogenous cytokines. The impaired degranulation against
an ovarian carcinoma cell line can be reversed by anti–
PD-L antibodies.
d PD-11 NK cells are present in higher proportions in the
ascites of a cohort of patients with ovarian carcinoma,
suggesting their possible induction/enrichment in tumor
microenvironment. Also in this case, PD-1 expression is
associated with impaired NK cell degranulation that is
reversible with anti–PD-L antibodies.
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mAbs
The following mAbs were isolated in our laboratory, licensed to the
indicated companies, and validated for their specificity: anti-2B4 (PP35, IgG1;
eBioscience Affymetrix, San Diego, Calif); anti–DNAM-1 (KRA236, IgG1),
anti-NKp30 (AZ20, IgG1), anti-NKp44 (Z231, IgG1), anti-NKp46 (BAB281,
IgG1; Beckman Coulter/Immunotech, Marseille, France), anti–Siglec-7
(QA79, IgG1; R&D Systems, Abingdon, United Kingdom), anti–Siglec-7
(Z176, IgG2b; Beckman Coulter/Immunotech, Marseille, France). For the
following mAbs, the specificity has been validated in the corresponding
patents or assigned to a cluster in CD workshop (see the indicated
link): anti–LIR-1 (F278, IgG1; www.hcdm.org/index.php?option5com_
molecule&cdnumber5CD85J), KIR3DL1/L2-S1 (AZ158, IgG2a; patents/
WO2010081890A1?cl5en), and CD160 (PAX71, IgG1; www.
sciencegateway.org/resources/prow/guide/1660590458_g.htm).
The purified anti–PD-1 mAb (PD1.3.1.3 clone, IgG2b) was originally
isolated at the Laboratoire Immunologie des Tumeurs, CRCM, Marseille-
Luminy (France),E1 whereas the anti–PD-1–phycoerythrin (PE) or anti–
PD-1–allophycocyanin (APC; clone PD1.3.1.3, IgG2b) was purchased from
Miltenyi Biotec (Bergisch Gladbach, Germany).
Additional mAbs used in this study were as follows: anti–B7-H3 (D-8,
IgG2b; Santa Cruz Biotechnology, Dallas, Tex), anti–IL-18Ra (B-E43, IgG1;
Abcam, Cambridge, United Kingdom), anti-ESA (IgG1; Novocastra Labora-
tories, Newcastle upon Tyne, United Kingdom), anti-CD90 (IgG1; BD Biosci-
ences PharMingen, San Jose, Calif), anti-KIR2DL1–PE or anti-KIR2DL1–
APC (143211 clone), anti-CD122 (27302 clone), anti-NKG2C–APC
(134591 clone), anti-NKG2C (134522 clone), anti–PD-L2 (176611 clone
IgG2b, R&D Systems), anti–PD-L2 (326.35 clone, IgG1),
E1 anti–PD-L1
(27A2, IgG2b; MBL, Woburn, Mass), anti–PD-L1 (PDL1.3.1 clone, IgG1),
E1
mixture of fluorescein isothiocyanate (FITC)–labeled CD3 plus PC5-labeled
CD56, anti-CD56–PC7 (N901 clone), anti-KIR3DL1/S1–APC (Z27 clone),
and anti-NKG2A–APC (Z199 clone) were purchased from Beckman
Coulter/Immunotech; anti-CD16–PerCP-Cy5.5 (clone 3G8), anti–
KIR2DL2/L3-S2–FITC (CH-L clone), anti–CD62 ligand (DREG-5 clone),
anti-CD107a–APCH7 (anti-LAMP1), and anti–IFN-g–PEwere fromBDBio-
sciences; and anti-KIR3DL1–FITC (DX9 clone), anti–KIR2DL2/L3-S2–APC
(DX27 clone), anti–KIR2DL1-S1 biotin-conjugated (11PB6 clone), anti-
CD3–VioGreen (BW264/56 clone), anti-CD20–VioGreen (LT20 clone),
anti-CD57–VioBlue (TB03 clone), anti–TNF-a–PE, and anti-biotin VioBlue
mAbs were purchased from Miltenyi Biotec. Anti-CD25 (clone BC96,
IgG1) and anti-CD69 (clone FN50, IgG1) were purchased from BioLegend
(San Diego, Calif).
Perforin and granzyme B expression analysis in NK cells was performed
with purified anti-perforinmAb fromAncell Corporation (Bayport,Minn) and
purified APC-labeled anti-granzyme B mAb from Invitrogen, respectively,
after cells were fixed and permeabilized with BD Cytofix/Cytoperm kit from
BD Biosciences PharMingen.
Isotype-specific goat anti-mouse secondary antibodies were purchased
from Southern Biotechnology (Birmingham, Ala) and, in the case of APC
IgG2b, by Jackson ImmunoResearch (Newmarket, United Kingdom).
For R-ADCC and masking experiments, additional mAbs isolated in our
laboratory and validated for their specificity were used: anti–HLA class I (A6/
136, IgM)E2 and anti-CD16 (c127, IgG1; Antibodies-Online, Aachen,
Germany).
The staining panels for every experiment are shown in Fig E2.
Cytofluorimetric analyses were performed on a FACSVerse (Becton
Dickinson, Mountain View, Calif), and data were analyzed with FACSuite
software version 1.0.3.
Analysis of NK cell degranulation and IFN-g and
TNF-a production
For the degranulation assay, PB lymphocytes were cultured overnight in the
presence of low doses of rhIL-15 (0.2 ng/mL) and then coincubated with oneof the following targets: (1) HLA class I K562 erythroleukemia target cells (a
classical target for natural cytotoxicity); (2) the FcgR1 P815murine mastocy-
toma cell line in the presence or absence of different mAbs specific for trig-
gering receptors in combination or not with PD-1, as indicated in the
appropriate figure (R-ADCC); and (3) the OVCAR5 ovarian carcinoma cell
line in the presence or absence of anti–PD-L-1/2 IgG1 mAbs (mAb-mediated
masking experiments) and anti-HLA I (A6/136) mAbs. Cocultures were per-
formed at an Effector/Target (E/T) ratio of 1:1 in a final volume of 200 mL in
round-bottom 96-well plates at 378C and 5% CO2 for 4 hours in culture me-
dium supplemented with anti-CD107a–PEmAb. After 1 hour of coincubation,
GolgiStop (BD Biosciences PharMingen) was added at a 1:100 dilution. Sur-
face staining was done by incubating the cells with anti-CD3, anti-CD56, anti-
CD20, and anti–PD-1 mAbs for 30 minutes at 48C. The cells were washed and
analyzed by using flow cytometry (FACSVerse, Becton Dickinson). Analysis
of NK cells was made on CD561CD32CD202 PD-11 or PD-12 gated cells.E3
The same experimental procedure was used to analyze PB and PF lympho-
cytes from patients with ovarian carcinoma. The target used in this case was
the OVCAR5 cell line in the presence of anti–HLA class I (A6/136) mAbs
in combination or not with anti–PDL-1/2 IgG1 mAbs, as indicated in the
appropriate figure.
PB lymphocytes were incubated with low doses of rhIL-15 (0.2 ng/mL)
overnight to detect intracellular production of IFN-g/TNF-a. Then
lymphocytes were washed and coincubated with target cells (K562 or P815
plus aCD16 in the presence or in the absence of aPD-1, as indicated in the
figures) at an E/T ratio of 1:1 in a final volume of 200 mL in round-botton
96-well plates at 378C and 5% CO2 for 4 hours in the presence of GolgiStop.
Thereafter, cells were washed, stained as described above for CD107a assays,
and then fixed and permeabilized with BD Cytofix/Cytoperm kit from BD
Biosciences PharMingen.E3 IFN-g and TNF-a production was detected by
mean of subsequent intracellular staining with anti–IFN-g–PE or anti–TNF-
a–PE and cytofluorimetric analysis. The percentage of positive cells was
calculated, subtracting the baseline CD107a/IFN-g/TNF-a expression in
control cultures without stimuli from targets.
CFSE analysis
The proliferative capability of PD-11 cell populations compared with PD-
12 NK cells was assessed by staining PB NK cells derived from PD-11 HDs
with CFSE before stimulation with rhIL-15 and rhIL-2 at different doses, as
indicated in Fig 7. In Fig 7, A, the analysis of PD-11 and PD-12 NK cell sub-
sets was made on CD56dimCD32CD202 gated cells.
In Fig 7, B and C, the analysis of NK cells was made on CD56dim NK cells
gated on NKG2A2KIR1CD571 cells, as indicated.
In Fig 7,C, proliferation analysis was performedwith FlowJo analysis soft-
ware, version 9.4.11 (TreeStar, Ashland, Ore).
ELISA
The seropositivity for HCMV in the HDs analyzed in this study was
detected by using Vironostika anti-CMV III (bioMerieux, Grenoble, France),
an ELISA for the detection of total antibody to CMV in human serum.REFERENCES
E1. Ghiotto M, Gauthier L, Serriari N, et al. PD-L1 and PD-L2 differ in their molec-
ular mechanisms of interaction with PD-1. Int Immunol 2010;22:651-60.
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FIG E1. A-D, Illustration of the gating strategies used in this study. In each square the inner frames indicate
the gated NK cell populations. FMO, Fluorescence minus one control. Right, Figures in which a given gate
strategy was used.
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Staining Panels of mAbs used in the various experiments
Strategy gate A/B Strategy gate C/D Strategy gate C
FLUOROCHROME Panel  Donors Screening Panel  Phenotype Panel  Perforin/Granzyme
mAb clone conjugation mAb clone conjugation mAb clone conjugation
FITC/CFSE KIRs
AZ158 IgG2a (L) 
+11PB6 +CHLEO 
IgG1 (C)
FITC            
(AZ158  purified)
PE X see "Appendix for X" Purified PD-1 PD1.3.1.3 IgG2b (L) Purified PD-1 PD1.3.1.3 IgG2b (C) PE
PerCp5.5 CD16 3G8 IgG1 (C) PerCp5.5 CD16 3G8 IgG1 (C) PerCp5.5 CD16 3G8 IgG1 (C) PerCp5.5
Pe-Cy7 CD56 N901   IgG1 (C) Pe-Cy7 CD56 N901   IgG1 (C) Pe-Cy7 CD56 N901   IgG1 (C) Pe-Cy7
APC NKG2A Z199 IgG2b (C) APC Z see "Appendix for Z"
APC-Cy7/APC-H7 Y see "Appendix for Y" Purified
VioBlue CD57 TB03 IgM (C) VioBlue
VioGreen CD3+CD20 BW264/56 IgG2a +     LT20 IgG1 (C) VioGreen CD3+CD20
BW264/56 IgG2a + 
LT20 IgG1 (C) VioGreen CD3+CD20
BW264/56 IgG2a +  
LT20 IgG1 (C) VioGreen
Appendix for X Appendix for Y Appendix for Z
mAb (X) clone mAb (Y) clone mAb (Z) clone conjugation
PD-1 PD1.3.1.3 IgG2b (L) NKp46 BAB281 IgG1 (L) Perforin deltaG9 IgG2b (C) Purified
B7-H3 D-8 IgG2b (C) NKp30 AZ20 IgG1 (L) Granzyme B GB12 IgG1 (C) APC
NKG2C 134522 IgG2b (C) NKp44 Z231 IgG1 (L)
Siglec-7 Z176 IgG2b (L) Siglec-7 QA79 IgG1 (L)
LIR-1 F278 IgG1 (L) Appendix for W
IL18Rα B-E43 IgG1 (L) mAb (W) clone
CD122 27302 IgG1 (C) IFN-γ B27 IgG1 (C)
CD62L DREG-5 IgG1 (C) TNF-α cA2 IgG1 (C)
CD160 PAX71 IgG1 (L)
2B4 PP35 IgG1 (L)
DNAM-1 KRA236 IgG1 (L)
NKG2C 134591 IgG1 (C)
CD69 FN50 IgG1 (C)
CD25 BC96 IgG1 (C)
Strategy gate C Strategy gate C Strategy gate C
FLUOROCHROME Panel  CD107a Panel  IFN-γ/TNF-α Panel  CFSE
mAb clone conjugation mAb clone conjugation mAb clone conjugation
FITC/CFSE CFSE
PE PD-1 PD1.3.1.3 IgG2b (L) Purified W see "Appendix for W" PE PD-1 PD1.3.1.3 IgG2b (L) Purified
PerCp5.5 CD16 3G8 IgG1 (C) PerCp5.5 CD16 3G8 IgG1 (C) PerCp5.5 CD16 3G8 IgG1 (C) PerCp5.5
Pe-Cy7 CD56 N901   IgG1 (C) Pe-Cy7 CD56 N901   IgG1 (C) Pe-Cy7 CD56 N901   IgG1 (C) Pe-Cy7
APC PD-1 PD1.3.1.3 IgG2b (L) KIRs Z27+ 11PB6 + DX27 IgG1 (C) APC
APC-Cy7/APC-H7 CD107a H4A3 IgG1 (C) APC-H7 NKG2A Z270 IgG1 (L) Purified
VioBlue CD57 TB03 IgM (C) VioBlue
VioGreen CD3+CD20 BW264/56 IgG2a +      LT20 IgG1 (C) VioGreen CD3+CD20
BW264/56 IgG2a +     
LT20 IgG1 (C) VioGreen CD3+CD20
BW264/56 IgG2a +       
LT20 IgG1 (C) VioGreen
C = Commercial mAbs
L= mAbs Isolated in our Laboratory
Note: In the APC-Cy7/APC-H7 channel, the fluorochrome used is always APC-Cy7, except in the CD107a degranulation experiments.
Further details on mAbs are included in the section "Monoclonal antibodies (mAbs)” in the Online Repository Material and Methods.
FIG E2. Staining panels ofmAbsused in the various experiments (functional and cell-surface/intra phenotypic
analysis).
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